Comparative Pharmacology
Head-to-head clinical analysis: METAHYDRIN versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAHYDRIN versus ORETIC.
METAHYDRIN vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic